Related Experiment Videos
Plasma exchange in systemic lupus erythematosus.
The International Journal of Artificial Organs
|July 1, 1983
Summary
Plasma exchange therapy showed promise for severe lupus erythematosus (SLE) patients unresponsive to conventional treatments. This approach led to improvements in some patients, highlighting its potential as an alternative therapy for SLE management.
Area of Science:
- Immunology
- Nephrology
- Rheumatology
Background:
- Severe Systemic Lupus Erythematosus (SLE) often necessitates aggressive treatment with steroids and cytotoxic drugs.
- Conventional therapies can lead to severe complications and side effects, including infections, organ failure, and secondary malignancies.
- Pathogenic mechanisms in SLE involve anti-DNA antibodies and immune complex deposition, contributing to inflammation and tissue damage.
Observation:
- Nine out of 20 SLE patients with rapidly progressive disease and contraindications for standard therapy were admitted to a plasma exchange program.
- Five patients experienced clinical improvement following plasma exchange.
- Two patients progressed to end-stage renal failure, and two died from SLE complications despite treatment.
Findings:
- Plasma exchange demonstrated a positive therapeutic effect in a subset of severe SLE patients.
- The study suggests that extracorporeal removal of immunopathogens may be beneficial in managing SLE.
- Treatment outcomes varied, with some patients showing significant improvement while others experienced disease progression or mortality.
Implications:
- Plasma exchange may serve as a viable alternative or adjunctive therapy for SLE patients who cannot tolerate or do not respond to conventional treatments.
- Further research is warranted to optimize plasma exchange protocols and identify patient subgroups most likely to benefit.
- Understanding the role of immunopathogens in SLE pathogenesis could lead to novel therapeutic strategies targeting immune complex removal or modulation.